1. A 54-year-old man with type 2 diabetes mellitus (T2DM) has a glycated hemoglobin (HbA1c) of 9.2 percent despite maximally tolerated metformin. His clinician wants the single injectable agent most likely to achieve near-normalization of glycemia. Based on head-to-head efficacy data, which choice is best supported?
A) A dual GIP/GLP-1 receptor agonist (tirzepatide), because it produced greater HbA1c reduction than semaglutide in a direct head-to-head trial in metformin-treated T2DM
B) A selective glucagon-like peptide-1 receptor (GLP-1R) agonist at low dose, because it lowers HbA1c more than any dual agonist
C) A sulfonylurea, because it produces greater durable HbA1c reduction than incretin-based agents
D) A sodium-glucose cotransporter-2 (SGLT-2) inhibitor, because it lowers HbA1c more than any injectable incretin agent
E) Basal insulin alone, because incretin agents do not lower HbA1c in metformin-treated patients
ANSWER: A
Rationale:
For a patient whose dominant goal is maximal glycated hemoglobin (HbA1c) reduction, the dual GIP/GLP-1 receptor agonist tirzepatide is best supported because, in a direct head-to-head trial in metformin-treated type 2 diabetes, it produced greater HbA1c reductions than semaglutide across its dose range.
Option B: Option B is incorrect because a selective GLP-1R agonist did not exceed the dual agonist on HbA1c reduction in the head-to-head comparison.
Option C: Option C is incorrect because sulfonylureas tend to lose efficacy over time and carry greater hypoglycemia risk, and they did not outperform incretin-based agents on durable glycemic control.
Option D: Option D is incorrect because SGLT-2 inhibitors produce more modest HbA1c reductions than high-dose incretin agonists and would not be the single agent most likely to near-normalize glycemia here.
Option E: Option E is incorrect because incretin agents do lower HbA1c effectively in metformin-treated patients, so basal insulin alone is not required for this goal.
2. A 47-year-old woman lost 18 percent of her body weight on a glucagon-like peptide-1 receptor (GLP-1R) agonist for obesity but must stop the drug because her insurance no longer covers it. She asks what to expect. Which counseling and plan are best supported?
A) Reassure her that weight loss is permanent because the drug reset her body weight set point
B) Tell her any weight regain would reflect only a lack of willpower unrelated to physiology
C) Explain that the drug overrode rather than reset her defended weight set point, so substantial weight regain over the following months is physiologically expected, and arrange behavioral support and a plan for re-initiation if coverage allows
D) Advise that stopping the drug abruptly will permanently suppress her appetite
E) Tell her that resuming the drug later would be ineffective because tolerance is permanent
ANSWER: C
Rationale:
The supported counseling explains that incretin agonists override rather than reset the hypothalamic set point that defends body weight; on discontinuation the orexigenic rebound is unmasked and substantial weight regain over the ensuing months is physiologically expected, so arranging behavioral support and a plan for re-initiation if coverage allows is appropriate.
Option A: Option A is incorrect because the set point is overridden, not permanently reset, so loss is not guaranteed to persist.
Option B: Option B is incorrect because regain is a predicted physiological consequence, not merely a failure of willpower.
Option D: Option D is incorrect because stopping the drug removes appetite suppression rather than permanently suppressing appetite.
Option E: Option E is incorrect because re-initiation can restore the pharmacological effect; tolerance is not permanent.
3. A 61-year-old man with type 2 diabetes on basal insulin and metformin is starting tirzepatide. His fasting glucose currently runs 120 to 140 mg/dL. What initial adjustment to his regimen most appropriately addresses hypoglycemia risk?
A) Increase the basal insulin dose by 20 percent to match the added agent
B) Reduce the basal insulin dose by approximately 20 percent at tirzepatide initiation and titrate further based on fasting glucose monitoring
C) Stop the basal insulin entirely and rely on tirzepatide alone from the first dose
D) Make no change to the insulin dose and recheck HbA1c in three months
E) Add a sulfonylurea to smooth the transition
ANSWER: B
Rationale:
When tirzepatide is added to basal insulin, reducing the basal insulin dose by approximately 20 percent at initiation, with subsequent titration guided by fasting glucose monitoring, appropriately mitigates the increased hypoglycemia risk from the combined glucose-lowering effect.
Option A: Option A is incorrect because increasing basal insulin would compound the glucose-lowering effect and raise hypoglycemia risk.
Option C: Option C is incorrect because abruptly stopping basal insulin in an insulin-requiring patient risks hyperglycemia and is not the recommended initiation step.
Option D: Option D is incorrect because leaving the insulin unchanged ignores the additive effect and increases hypoglycemia risk.
Option E: Option E is incorrect because adding a sulfonylurea would further increase hypoglycemia risk rather than reduce it.
4. A 38-year-old woman with obesity and prediabetes requests tirzepatide for weight management. Her mother and brother both had medullary thyroid carcinoma (MTC), and genetic testing confirmed multiple endocrine neoplasia type 2 (MEN2) in the family. What is the most appropriate action?
A) Prescribe tirzepatide at the standard starting dose, since family history is not relevant
B) Prescribe tirzepatide but order thyroid ultrasound monitoring every month during therapy
C) Prescribe a triple agonist instead, which carries no thyroid-related contraindication
D) Do not prescribe tirzepatide, because a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) is a contraindication to this drug class
E) Prescribe tirzepatide only if she agrees to prophylactic thyroidectomy first
ANSWER: D
Rationale:
A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) is a contraindication to tirzepatide and the glucagon-like peptide-1 receptor (GLP-1R) agonist class, so the agent should not be prescribed in this patient.
Option A: Option A is incorrect because family history of MTC or MEN2 is precisely the relevant contraindication.
Option B: Option B is incorrect because monitoring does not override an absolute class contraindication; the drug should be avoided rather than prescribed with surveillance.
Option C: Option C is incorrect because triple agonists share the same incretin-based class concern and are investigational, so they are not an appropriate contraindication-sparing substitute.
Option E: Option E is incorrect because prophylactic thyroidectomy is not an accepted means of enabling use of a contraindicated drug for weight management.
5. A 56-year-old man with type 2 diabetes mellitus (T2DM), a body mass index of 34, and biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) with stage F3 fibrosis needs pharmacotherapy with hepatic benefit. He also has a history of lower-extremity edema. Which agent is the better choice, and why?
A) Pioglitazone, because its weight gain is beneficial in this setting
B) Pioglitazone, because it has no effect on fluid balance or bone
C) Tirzepatide, because it provides glycemic control, substantial weight loss, and direct hepatic benefit, whereas pioglitazone promotes weight gain, fluid retention that could worsen his edema, and bone loss
D) Neither agent has any role in MASH, so no pharmacotherapy should be offered
E) A sulfonylurea, because it is the preferred agent for MASH with fibrosis
ANSWER: C
Rationale:
Tirzepatide is the better choice because it offers glycemic control, substantial weight loss, and direct hepatic benefit in MASH, while its weight reduction itself ameliorates hepatic steatosis and inflammation; pioglitazone, although histologically active in MASH, promotes weight gain, fluid retention that could worsen this patient's edema, and bone loss.
Option A: Option A is incorrect because weight gain is not beneficial in an obese patient with MASH.
Option B: Option B is incorrect because pioglitazone does cause fluid retention and bone loss.
Option D: Option D is incorrect because effective pharmacotherapy with hepatic benefit exists and should be offered.
Option E: Option E is incorrect because sulfonylureas are not preferred agents for MASH and lack demonstrated histological benefit.
6. A 68-year-old woman with a body mass index of 36 has heart failure with preserved ejection fraction (HFpEF), with dyspnea on exertion and a markedly reduced exercise tolerance. She does not have diabetes. Her cardiologist asks how incretin-based therapy fits into her management. Which statement is most accurate?
A) Incretin therapy is contraindicated in HFpEF because weight loss impairs cardiac filling
B) Incretin therapy should replace all other heart failure therapies as first-line treatment
C) Incretin therapy has no role because obesity does not contribute to HFpEF
D) Incretin therapy is useful only if she develops diabetes
E) Weight reduction with incretin-based therapy can improve symptoms in obesity-related HFpEF, with a dual GIP/GLP-1 agonist also reducing cardiovascular death or worsening heart failure events, while sodium-glucose cotransporter-2 (SGLT-2) inhibitors retain the strongest HFpEF outcome evidence regardless of obesity status
ANSWER: E
Rationale:
In obesity-related HFpEF, weight reduction with incretin-based therapy can improve symptom burden and functional capacity, and a dual GIP/GLP-1 agonist additionally reduced the composite of cardiovascular death or worsening heart failure events; nonetheless, sodium-glucose cotransporter-2 (SGLT-2) inhibitors retain the strongest HFpEF outcome evidence regardless of obesity status, so incretin therapy complements rather than replaces guideline therapy.
Option A: Option A is incorrect because incretin therapy is beneficial, not contraindicated, in obesity-related HFpEF.
Option B: Option B is incorrect because incretin therapy complements rather than replaces established heart failure treatment.
Option C: Option C is incorrect because obesity is a central mechanistic driver of this HFpEF phenotype.
Option D: Option D is incorrect because the benefit in obesity-related HFpEF does not require the presence of diabetes.
7. A 44-year-old woman started a dual GIP/GLP-1 agonist eight weeks ago and was increased to the next dose two weeks ago. Since then she has had bothersome nausea and occasional vomiting but no abdominal pain, no signs of pancreatitis, and stable vital signs. What is the most appropriate next step?
A) Discontinue the drug permanently and avoid the entire class for life
B) Hold further dose escalation and maintain the current or prior tolerated dose to allow gastrointestinal accommodation, since these dose-related effects are usually transient
C) Increase the dose further to accelerate tolerance
D) Add a second incretin agonist to offset the nausea
E) Order urgent surgical evaluation for bowel obstruction despite the benign examination
ANSWER: B
Rationale:
The gradual titration schedule exists to allow gastrointestinal accommodation and limit dose-related nausea, vomiting, and diarrhea; for a patient with bothersome but uncomplicated symptoms and a benign examination, holding further escalation and maintaining the current or last tolerated dose to allow accommodation is appropriate, as these effects are usually transient.
Option A: Option A is incorrect because uncomplicated, dose-related gastrointestinal effects do not warrant permanent discontinuation or lifelong class avoidance.
Option C: Option C is incorrect because increasing the dose would worsen the dose-related effects.
Option D: Option D is incorrect because adding a second incretin agonist is a redundant, higher-risk overlap that would not relieve nausea.
Option E: Option E is incorrect because the benign examination and absence of obstructive features do not support urgent surgical evaluation.
8. A 50-year-old man with type 2 diabetes is currently on weekly semaglutide. Frustrated with his progress, he asks his clinician to add tirzepatide on top of the semaglutide for a stronger effect. What is the most appropriate response?
A) Do not combine the two agents; because tirzepatide and a glucagon-like peptide-1 receptor (GLP-1R) agonist have overlapping mechanisms with no additive benefit and increased adverse-effect risk, the appropriate option is to switch from semaglutide to tirzepatide rather than stack them
B) Add tirzepatide to the semaglutide, since combining two incretin agonists doubles the benefit
C) Add tirzepatide and also start pramlintide for a triple incretin effect
D) Keep both drugs but halve the dose of each to avoid overlap
E) Add tirzepatide only on alternating weeks with semaglutide
ANSWER: A
Rationale:
Tirzepatide should not be combined with a glucagon-like peptide-1 receptor (GLP-1R) agonist such as semaglutide because the overlapping mechanisms provide no additive benefit and increase adverse-effect risk; the appropriate option for a patient seeking greater effect is to switch from semaglutide to tirzepatide rather than stack the two.
Option B: Option B is incorrect because combining two incretin agonists does not double benefit and raises adverse-effect risk.
Option C: Option C is incorrect because adding pramlintide compounds the overlapping mechanisms and risk without added benefit.
Option D: Option D is incorrect because halving doses of two overlapping agents does not create a rational regimen; switching is preferred.
Option E: Option E is incorrect because alternating two overlapping GLP-1R-active agents is not an evidence-based strategy and still represents inappropriate overlap.
9. A 31-year-old woman with type 2 diabetes mellitus (T2DM) controlled on tirzepatide tells her clinician she plans to conceive in the next several months. How should her glucose-lowering therapy be managed in anticipation of pregnancy?
A) Continue tirzepatide throughout conception and pregnancy at the same dose
B) Continue tirzepatide until a positive pregnancy test, then stop the same day
C) Discontinue tirzepatide at least two months before planned conception and transition to insulin, which is the preferred glucose-lowering agent in pregnancy
D) Switch to a sulfonylurea as the preferred agent during pregnancy
E) Increase the tirzepatide dose to optimize control before conception
ANSWER: C
Rationale:
Tirzepatide should be discontinued at least two months before planned conception, with transition to insulin, which is the preferred glucose-lowering agent in pregnancy.
Option A: Option A is incorrect because tirzepatide is not used during pregnancy and should be stopped in advance of conception.
Option B: Option B is incorrect because the recommended discontinuation is at least two months before conception rather than at the time of a positive pregnancy test.
Option D: Option D is incorrect because insulin, not a sulfonylurea, is the preferred agent in pregnancy.
Option E: Option E is incorrect because increasing the dose runs counter to the need to discontinue the drug before conception.
10. A 64-year-old man with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease (ASCVD) needs an injectable incretin agent primarily for cardiovascular risk reduction. He is weighing tirzepatide against a cardioprotective glucagon-like peptide-1 receptor (GLP-1R) agonist. Which approach is best supported?
A) Only the GLP-1R agonist can be used, because the dual agonist increases cardiovascular risk
B) Only the dual agonist can be used, because GLP-1R agonists have no cardiovascular benefit
C) Neither agent should be used in patients with established ASCVD
D) Either agent is reasonable for cardiovascular risk reduction because both reduce major adverse cardiovascular events, so the choice can be guided by cost, tolerability, and formulary access
E) Both agents should be used together to maximize cardiovascular protection
ANSWER: D
Rationale:
For cardiovascular risk reduction in T2DM with established ASCVD, either tirzepatide or a cardioprotective GLP-1R agonist is reasonable because both reduce major adverse cardiovascular events, so the selection can be guided by cost, tolerability, and formulary access.
Option A: Option A is incorrect because the dual agonist preserves the cardiovascular protection of the incretin class rather than increasing risk.
Option B: Option B is incorrect because GLP-1R agonists do have established cardiovascular benefit.
Option C: Option C is incorrect because incretin-based agents are appropriate and beneficial in patients with established ASCVD.
Option E: Option E is incorrect because the two agents have overlapping mechanisms and should not be combined.
11. A 45-year-old man with type 2 diabetes mellitus (T2DM) would benefit from incretin therapy but has a severe needle phobia and has declined all injectable options. He also struggles to follow strict fasting-and-wait dosing instructions. Among emerging therapies, which approach best fits his needs, and why?
A) An injectable dual GIP/GLP-1 agonist administered by a caregiver, since oral incretin therapy is impossible
B) Oral peptide semaglutide, because it can be taken with food at any time without special instructions
C) A compounded injectable formulation, because compounding converts it to an oral product
D) No incretin therapy is possible without injection
E) An oral non-peptide small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist, because its conventional small-molecule absorption avoids both injection and the permeation enhancer and strict fasting required by peptide oral semaglutide
ANSWER: E
Rationale:
An oral non-peptide small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist best fits this patient because its oral bioavailability comes from conventional small-molecule absorption, avoiding both injection and the permeation enhancer plus strict fasting administration that peptide oral semaglutide requires.
Option A: Option A is incorrect because effective oral incretin therapy is feasible, so caregiver-administered injection is not the only path.
Option B: Option B is incorrect because oral peptide semaglutide requires a permeation enhancer and strict fasting administration, not dosing with food at any time.
Option C: Option C is incorrect because compounding does not convert an injectable product into an oral one.
Option D: Option D is incorrect because emerging oral agents make non-injection incretin therapy possible.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.